Skip to content

Heart Failure with Reduced Ejection Fraction

NO LONGER ACCEPTING APPLICATIONS
Published on:
September 18, 2024
Sign-up Expiration:
Updated:
Topics:
Locations:

This study will evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-861 administered once daily for 12 weeks in subjects with heart failure with reduced ejection fraction (HFrEF) who are on a stable, guideline-directed medical therapy for heart failure.

View Additional Information
View Clinical Trial Attachment
Sign Up NowExpired - View Other Trials
ENDED